Sekar Kathiresan - Feb 14, 2024 Form 4 Insider Report for Verve Therapeutics, Inc. (VERV)

Role
Chief Executive Officer, Director
Signature
/s/ Andrew Ashe, as Attorney-in-Fact for Sekar Kathiresan
Stock symbol
VERV
Transactions as of
Feb 14, 2024
Transactions value $
$0
Form type
4
Date filed
2/16/2024, 04:30 PM
Previous filing
Jun 1, 2023
Next filing
Jun 5, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VERV Stock Option (right to buy) Award $0 +526K $0.00 526K Feb 14, 2024 Common Stock 526K $12.75 Direct F1
transaction VERV Restricted Stock Units Award $0 +132K $0.00 132K Feb 14, 2024 Common Stock 132K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted on February 14, 2024. 25% of the shares underlying the option will vest on February 14, 2025, and the remainder are scheduled to vest in equal monthly installments thereafter until February 14, 2028.
F2 Each restricted stock unit represents a contingent right to receive one share of common stock.
F3 On February 14, 2024, the reporting person was granted restricted stock units, vesting in four equal annual installments, beginning on April 1, 2025, and the remaining three installments vesting on April 1, 2026, April 1, 2027 and April 1, 2028.